Endocrine Abstracts

For the purpose to compare sleep breathing disorders (SBD) in untreated and treated patients with acromegaly, we examined 55 patients with acromegaly (18 men and 37 women): 27 patients with newly diagnosed acromegaly, age 56.0 (47.0; 64.0) y.o., BMI 30.2 (27.8; 34.4) kg/m2, GH levels 12.8 (4.6; 23.0) ng/ml, IGF-1 245 (106; 331) % of upper normal limit (UNL), hypertension duration 6.5 (1.0; 14.8) years; 28 patients with treated acromegaly, age 57.0 (47.3; 64.8) y.o., BMI 30.7 (27.9; 35.0) kg/m2, GH levels 2.1 (1.2; 3.4) ng/ml, IGF-1 14 (7; 21) % UNL, hypertension duration 9.0 (3.0; 10.0) years. Data are expressed in Median (25%;75%). Respiratory monitoring was conducted using device ApneaLink, ResMedInc, Australia. Statistical analysis: SPSSv.22. High index of apnoe-hypopnoe (IAH) was found in 91.9% untreated and in 78.6% treated patients: severe SBD in 51.9% and 46.5% patients (IAH 46.6 (40.8; 57.8) and 47.0 (43.9; 59.0), respectively); moderate SBD – in 25.9% and 21.4% (IAH 21.3 (20.0; 23.0) and 23.2 (18.0; 26.3)), mild – in 14.8% and 10.7% (IAH 10.5 (8.3; 12.1) and 5.0 (5.0; 11.0)). The saturation level (normally 94-98%) was decreased in 54.2% untreated and 42.3% treated patients; the average saturation level was 93.0 (90.0; 94.0)% and 94.0 (91.8; 95.3)%, correspondingly. Desaturation level (normally 90-98%) was below normal in 91.7% untreated and 83.3% treated patients; the average desaturation was 79.5 (70.3; 86.8) % and 84 (72.3; 88.8) %, respectively. Severity of SBD did not correlated with GH/IGF-1 levels. Moderate correlations were found between IAH and age, IAH and duration of hypertension. Thus, sleep breathing disorders (with high prevalence of severe IAH and significant desaturation) could be found in most of the patients with untreated and treated acromegaly, and regression of SBD after acromegaly treatment is not so significant. Specific methods of apnoe treatment should be considered for patients with acromegaly and SBD.